NASDAQ:CDTX - Cidara Therapeutics Stock Price, Forecast & News

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Cidara Therapeutics Inc (NASDAQ:CDTX) released its earnings results on Thursday, November, 7th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.34. The biotechnology company earned $19.10 million during the quarter, compared to analyst estimates of $30 million. View Cidara Therapeutics' Earnings History.

Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Cidara Therapeutics.

6 equities research analysts have issued 12 month target prices for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Cidara Therapeutics' stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 137.1% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics.

Media coverage about CDTX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cidara Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Cidara Therapeutics.

Cidara Therapeutics saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 1,860,000 shares, an increase of 51.2% from the January 30th total of 1,230,000 shares. Based on an average daily volume of 341,100 shares, the short-interest ratio is currently 5.5 days. Currently, 9.0% of the company's stock are short sold. View Cidara Therapeutics' Current Options Chain.

Some companies that are related to Cidara Therapeutics include Harpoon Therapeutics (HARP), BioCryst Pharmaceuticals (BCRX), Cabaletta Bio (CABA), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Gritstone Oncology (GRTS), Novavax (NVAX), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), Brainstorm Cell Therapeutics (BCLI), ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI), LogicBio Therapeutics (LOGC), La Jolla Pharmaceutical (LJPC) and Jounce Therapeutics (JNCE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Agile Therapeutics (AGRX) and Viking Therapeutics (VKTX).

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Cidara Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include 5AM Venture Management LLC (6.07%), Renaissance Technologies LLC (2.41%), Bank of Montreal Can (0.54%), Oxford Asset Management LLP (0.52%), Jacobs Levy Equity Management Inc. (0.44%) and Raymond James Financial Services Advisors Inc. (0.38%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala. View Institutional Ownership Trends for Cidara Therapeutics.

CDTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, Neil Abdollahian and Paul Daruwala. View Insider Buying and Selling for Cidara Therapeutics.

CDTX stock was bought by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Bank of Montreal Can, Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, Banco Bilbao Vizcaya Argentaria S.A. and Marshall Wace LLP. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine and Jeffrey Stein. View Insider Buying and Selling for Cidara Therapeutics.

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDTX stock can currently be purchased for approximately $2.90.

Cidara Therapeutics has a market capitalization of $95.82 million. The biotechnology company earns $-59,020,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.View Additional Information About Cidara Therapeutics.

The official website for Cidara Therapeutics is http://www.cidara.com/.

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]